Scottish HTA Reverses No For Yescarta
Executive Summary
The Scottish health technology appraisal body, the SMC, has okayed Gilead’s CAR-T therapy Yescarta for use on the Scottish National Health Service.
You may also be interested in...
Scotland’s SMC OKs Drugs For Cancer & Plaque Psoriasis
The Scottish Medicines Consortium has OKd Keytruda, Decapeptyl, Yescarta and Skyrizi after patient access schemes were agreed that improved their cost-effectiveness. But Perjeta and Xtandi were rejected because the companies made no solid economic case for NHS funding.
Scottish HTA OKs Kymriah For Lymphoma After Novartis Drops Price
Scotland’s health technology assessment body has reversed its earlier decision to reject Kymriah for DLBCL.
Payment For Outcomes Key To EU Market Access for Yescarta
Payment for outcomes has played an important role in enabling Gilead to secure reimbursement for Yescarta in some EU markets. It is likely to be the key focus for the company as it works to expand patient access to the potentially transformative CAR-T therapy across Europe.